IMR Press / EJGO / Volume 30 / Issue 3 / pii/2009079

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report

Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy

Show Less
1 Departments of Oncology & Radiotherapy, Palacký University Medical School & Teaching Hospital, Olomouc (Czech Republic)
2 Departments of Medical Genetics, Palacký University Medical School & Teaching Hospital, Olomouc (Czech Republic)
3 Departments of Pathology, Palacký University Medical School & Teaching Hospital, Olomouc (Czech Republic)
4 Departments of Nuclear Medicine, Charles University Medical School & Teaching Hospital, Hradec Králové (Czech Republic)
5 Department of Oncology, Palacký University Medical School & Teaching Hospital, Olomouc (Czech Republic)
Eur. J. Gynaecol. Oncol. 2009, 30(3), 323–325;
Published: 10 June 2009
Abstract

We present here a case of a BRCA1 mutation carrier with repeat responsiveness of recurrent EOC to paclitaxel/platinum. The patient had complete response to the combination of paclitaxel/platinum in the first line. Subsequent four recurrences also showed a complete response to this combination. The chronic toxicity, including hypersensitivity and nephrotoxicity could be controlled by modifying the regimen. In conclusion, recurrent EOC in BRCA1 mutation carriers may retain sensitivity to paclitaxel/platinum com-bination chemotherapy, and this combination could be therapy of first choice in this patient population.

Keywords
BRCA1
Epithelial ovarian carcinoma
Paclitaxel
Platinum
Share
Back to top